The observation that TNF-α, a major cytokine present in the rheumatoid joints, stimulates the NF-κB signaling pathway has led to the approval of several TNF-α blockers in RA [5], and similar considerations might be given to the use of TNF-β in the future. The gene discussed is TNF; the disease is rheumatoid arthritis.